DE69614392T2 - Thrombin inhibitor - Google Patents

Thrombin inhibitor

Info

Publication number
DE69614392T2
DE69614392T2 DE69614392T DE69614392T DE69614392T2 DE 69614392 T2 DE69614392 T2 DE 69614392T2 DE 69614392 T DE69614392 T DE 69614392T DE 69614392 T DE69614392 T DE 69614392T DE 69614392 T2 DE69614392 T2 DE 69614392T2
Authority
DE
Germany
Prior art keywords
thrombin inhibitor
compounds
arterial
inflammation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69614392T
Other languages
English (en)
Other versions
DE69614392D1 (en
Inventor
F Bone
M Soll
R Illig
Tianbao Lu
L Subasinghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69614392D1 publication Critical patent/DE69614392D1/de
Publication of DE69614392T2 publication Critical patent/DE69614392T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69614392T 1995-06-07 1996-06-07 Thrombin inhibitor Expired - Fee Related DE69614392T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,421 US5612369A (en) 1995-06-07 1995-06-07 Thrombin inhibitors
PCT/US1996/009806 WO1996040118A1 (en) 1995-06-07 1996-06-07 Thrombin inhibitors

Publications (2)

Publication Number Publication Date
DE69614392D1 DE69614392D1 (en) 2001-09-13
DE69614392T2 true DE69614392T2 (de) 2002-05-08

Family

ID=23935660

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69614392T Expired - Fee Related DE69614392T2 (de) 1995-06-07 1996-06-07 Thrombin inhibitor

Country Status (10)

Country Link
US (1) US5612369A (de)
EP (1) EP0841918B1 (de)
JP (1) JPH11507366A (de)
AT (1) ATE203905T1 (de)
AU (1) AU6108196A (de)
CA (1) CA2223500A1 (de)
DE (1) DE69614392T2 (de)
ES (1) ES2161365T3 (de)
GR (1) GR3036750T3 (de)
WO (1) WO1996040118A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
KR100377558B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
KR100377557B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 아실 구아니딘 작용기를 갖는 선택적 트롬빈 억제제
ATE532058T1 (de) 2004-05-17 2011-11-15 Medtronic Inc Point-of-care-heparinbestimmungssystem
US7754755B2 (en) * 2004-09-23 2010-07-13 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US11404815B2 (en) 2017-10-30 2022-08-02 Ormond Energy Innovations Inc. Sealed connector with triggered mating and method of using same
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
US4767744A (en) * 1986-07-14 1988-08-30 G. D. Searle & Co. Substituted tyrosyl methionyl dipeptide amides
WO1993015756A1 (en) * 1992-02-14 1993-08-19 Corvas International, Inc. Inhibitors of thrombosis
US5248673A (en) * 1992-12-23 1993-09-28 Bristol-Myers Squibb Co. Bisamidine derivatives as thrombin inhibitors
ATE153670T1 (de) * 1993-03-03 1997-06-15 Sandoz Ag Peptidboronsäurederivate mit protease inhibierenden aktivität
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.

Also Published As

Publication number Publication date
JPH11507366A (ja) 1999-06-29
EP0841918A1 (de) 1998-05-20
AU6108196A (en) 1996-12-30
ES2161365T3 (es) 2001-12-01
DE69614392D1 (en) 2001-09-13
US5612369A (en) 1997-03-18
GR3036750T3 (en) 2001-12-31
WO1996040118A1 (en) 1996-12-19
CA2223500A1 (en) 1996-12-19
ATE203905T1 (de) 2001-08-15
EP0841918A4 (de) 1998-10-21
EP0841918B1 (de) 2001-08-08

Similar Documents

Publication Publication Date Title
EA200300306A1 (ru) Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DE69410092T2 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
ATE203905T1 (de) Thrombin inhibitor
DE69529690D1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
ATE185558T1 (de) Prostaglandin-synthase hemmer
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
PT705100E (pt) Guanidinas substituidas terapeuticas
EA200201175A1 (ru) Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
NO980643L (no) Propylendopeptidase inhibitorer
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
ES2142490T3 (es) Ciclopeptolidos.
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
FI963168A0 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
HUP9902417A2 (hu) Alfa-ketoészterek, és alfa-ketoamidok acilezett enol-származékai
DE69527854T2 (de) Derivate substituierter amidinonaphthylester
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE69902142D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
MX9709386A (es) Derivados del arilsulfonilaminobenceno y el uso de los mismos como inhibidores del factor xa.
DK1042297T3 (da) Carboxylsyresubstituerede heterocykliske forbindelser som metalloproteinaseinhibitorer

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee